Life expectancy of at least  months from most recent chemotherapy or immunotherapy treatment
No comorbid conditions that would cause life expectancy of less than  years
Patients must have a life expectancy of >=  weeks as determined clinically by the treating physician
Life expectancy of at least  weeks based on investigator estimate
Have ECOG PS of  or  with an anticipated life expectancy of >  months.
Life expectancy < years
Life expectancy of >  months as defined by agreement of both the Chow et al. and TEACHH models
SAFETY RUN-IN: Life expectancy of less than  months
Subject must have a life expectancy >=  years
PIKCA WILD TYPE COHORT (closed //): Life expectancy >  months
Patients with life expectancy >=  weeks from time of CTL infusion
Life expectancy of at least  months in the judgment of the physician
No prior primary or metastatic brain or meningeal tumors unless clinically and radiographically stable as well as off steroid therapy for at least  months; a. Life expectancy ? weeks all (US); b. Life expectancy ? weeks; ?  weeks superficial tumors (Canada);
Patients with short life expectancy (less than  months) due to comorbidity other than MDS or CMML
Life expectancy ? mos
Life expectancy ? years, as judged by the site investigator
Life expectancy of less than  months in the judgment of the study physician.
Patients with a life expectancy <  months from co-existing disease other than the leukemia or RAEB
Life expectancy >=  days
Must have a life expectancy of at least  years based on age and comorbidities but excluding diagnosis of breast cancer.
Patients with a life expectancy of less than  years
No active or co-existing malignancy with life expectancy less than  months
No active or co-existing malignancy with life expectancy less than  months
Life expectancy >=  weeks as judged by the treating physician.
Life expectancy >=  days
Co-existing medical conditions with life expectancy <  years
Patients with a life expectancy of <  months of enrollment from coexisting disease other than leukemia
Life expectancy less than  years;
Patients must have life-expectancies >  months to be included in the trial
Life expectancy of at least  years
Life expectancy >=  months at the time of study drug administration
Minimum life expectancy of at least  weeks. Expanded Safety Phase:
Patients with any severe concomitant disease that may limit their life expectancy to less than  years
Life expectancy of ?  months from the first OBP- treatment.
Life expectancy <  months (as estimated per diagnosis-specific graded prognostic assessment [ds-GPA])
Life expectancy of over  months as determined by treating physician
Life expectancy less than  years
Patients with short life expectancy (less than  months) due to comorbidity other than MDS
Life expectancy of >=  weeks based on investigator estimate
ECOG Grade  - , with minimum life expectancy of at least  months;
Patients with life expectancy of =<  months for reasons other than their underlying hematologic/oncologic disorder
Presence of other comorbid illnesses with an estimated median life expectancy <  years
Subject has an ECOG Performance Status - and anticipated life expectancy > months prior to apheresis and > months prior to lymphodepletion.
Life expectancy of greater than  months (does not apply to pancreatic cancer population)
Have at least  month life expectancy
Subjects must have a reasonable life expectancy of at least  months
Life expectancy =<  months in the judgment of the treating clinician
Life expectancy > weeks as judged by investigators
Life expectancy of >=  weeks (per treating investigators discretion)
Life expectancy >=  years (as determined by the treating physician)
CAPMATINIB INCLUSION CRITERIA: Life expectancy >=  weeks
CERITINIB INCLUSION CRITERIA: Life expectancy >=  weeks
Patients with life expectancy of =<  months for reasons other than their underlying hematologic/oncologic disorder
No active or co-existing malignancy with life expectancy less than  months
Life expectancy >=  weeks excluding their diagnosis of breast cancer
Life expectancy with treatment should be >=  months in the estimation of the treating physicians
A life expectancy of at least  weeks, even if requiring artificial ventilation.
Life expectancy of at least  years
Life expectancy of >=  years (yrs)
Other serious medical conditions that may be expected to limit life expectancy to less than  years (e.g., liver cirrhosis).
At least  month life expectancy
Life expectancy >  years
Must have a life expectancy of at least  years based on age and co-morbidities.
Patients with life expectancy of =<  months for reasons other than their underlying hematologic/oncologic disorder
Life expectancy of greater than  months to allow completion of study treatment and assessment of dose-limiting toxicity
Patients with life expectancy of =<  months for reasons other than their underlying hematologic/oncologic disorder
A life expectancy of at least  months with a Karnofsky performance status of at least 
Patients with life expectancy of =<  months for reasons other than their underlying hematologic/oncologic disorder
Minimum life expectancy of six weeks as determined by consenting professional
No life expectancy restrictions will apply
Life expectancy of >=  years as determined by treating physician
Patients with co-existing medical conditions with life expectancy <  years
Life expectancy reasonably adequate for evaluating the treatment effect
A serious underlying medical condition other than NSCLC such that life expectancy is less than  years.
INCLUSION CRITERIA FOR CCT: minimum life expectancy of eight weeks
life expectancy of less than  months; Related to anticoagulant treatment:
Life expectancy of at least  days
Stable clinical conditions and life expectancy >  months
Other life-threatening illness that is expected to impact life expectancy within  years
The patient has a prior or concurrent malignancy that in the opinion of the investigator, presents a greater risk to the patients health and survival, than of the MCL with a life expectancy <  years.
Life expectancy of >=  months in the attending physicians estimation
Life expectancy estimate >  months
Life expectancy of >  years per the clinical impression of the treating physician(s)
Life expectancy >  months as assessed by study physician
TUMOR BIOPSY SEQUENCING: Life expectancy >  months
Life expectancy of >=  years
Minimum expected life expectancy >  months
<  years life expectancy
Life expectancy <  years
Life expectancy of at least  months based on Investigators judgment.
Life expectancy ?  years
Life expectancy of at least  years, disregarding the diagnosis of cancer;
ECOG Performance Status - and anticipated life expectancy >  months.
Patients with other active malignancies (no evidence of other cancer or life expectancy greater than  years) are ineligible for this study
Life expectancy ?  years.
Life expectancy >=  months at the time of study drug administration
Diagnosis of a coexisting medical condition which limits life expectancy to <  years
Life expectancy of at least  years
Life expectancy <  days.
Have ECOG PS of  or  with an anticipated life expectancy of >  months.
Patients must have an anticipated life expectancy >  months.
Patients must have a life expectancy of >=  days
Life expectancy <  months as assessed by the treating physician
Patient ?  years of age. Patient life expectancy >  months. Eastern cooperative group (ECOG) of  or 
Life expectancy >  years
Life expectancy of at least  years from the time of diagnosis, not considering the melanoma in question, as determined by the PI.
Life expectancy of < months and/or has rapidly progressing disease
Subject must be ?  years of age. Life expectancy >  weeks.
Patients must have a life expectancy >=  days
Life expectancy >=  months as determined by the treating physician
Life expectancy >  month
Life expectancy <  years
Patients with life expectancy of =<  months for reasons other than their underlying hematologic/oncologic disorder
At least -month life expectancy.
Life expectancy >  years based on clinicians judgment
Life expectancy less than  month
Patients with a life expectancy <  months from co-existing disease other than the leukemia or RAEB
Patients may have received therapy for other malignancies, as long as they have completed therapy at least  months prior to study entry and be deemed to have a life expectancy of at least  years with regard to that malignancy
Life expectancy >=  mos
Other serious medical conditions that may be expected to limit life expectancy to less than  years (e.g., liver cirrhosis).
Life-expectancy based on comorbid conditions >  years
Patients must have a life expectancy of >=  months and a Karnofsky performance status >= 
Life expectancy from a co-morbid illness >  years
Known history of or concomitant malignancy likely to affect life expectancy in the judgment of the investigator
Life expectancy of at least  years
Any available standard line of therapy known to be life-prolonging or life-saving
Life expectancy of at least  weeks ( months) as determined by the treating physician.
Patients with life expectancy of =<  months for reasons other than their underlying hematologic/oncologic disorder or complications there from
Anticipated life expectancy > months at the time of screening
Anticipated life expectancy > months at the time of screening
Life-expectancy of at least  days
Life expectancy of at least  months in the judgment of the physician
are eligible for any standard therapy known to be life prolonging or life saving
History of second malignancies with life expectancy of <  years or requirement of therapy that would confound study results. This does not include the following:
Life expectancy >mo.
Any co-morbid condition that poses a greater threat to the patients life expectancy than the recurrent myeloma
No concurrent malignancy with a life expectancy of less than two years, or one that requires ongoing chemotherapeutic intervention at screening
Subject has concurrent severe or uncontrolled medical disease or organ system dysfunction which, in the opinion of the Investigators, would limit life expectancy to <  months.
Anticipated life expectancy >  months at the time of screening
Not eligible for or declined transplantation or any standard therapy known to be life prolonging or life saving
Patients life expectancy is >=  years
Patients with other active malignancies (no evidence of other cancer or life expectancy greater than  years) are ineligible for this study
Life expectancy of at least  month
Life expectancy of at least  months in the judgment of the physician
No co-existing medical conditions with life expectancy <  years
PATIENT EXCLUSION: Life expectancy of <  month
Patients must have a life expectancy of  days
Must have a life expectancy >  days
There are no restrictions related to performance status or life expectancy
Patients with a life expectancy of =<  months, as determined by their oncology providers, will be excluded
Patients are eligible regardless of life expectancy
PATIENTS ONLY: Physician-rated life expectancy of less than  months
Attending physician assessment of prognosis with expected life expectancy of >  months
Severe co-existing morbidities having a life expectancy of less than  days
No life expectancy restriction
There are no restrictions related to performance status or life expectancy
Has a life expectancy of  months or longer; all cancer types are included
There are no restrictions related to performance status and life expectancy
Life expectancy >=  days
Have a life expectancy > months from the anticipated time of initiation of treatment
Participants must have a life expectancy of  years or more
>=  months life expectancy (physician estimate)
No restrictions will be made based on life expectancy
Life expectancy less than  years
EXCLUSION CRITERIA FOR ENROLLMENT (PRE-TRANSPLANT): Non-hematologic malignancy with a life expectancy of <  years
Suffering from a terminal illness with less than  month life expectancy
Terminal illness with less than  month life expectancy
Subjects with a life expectancy less than study duration;
Life expectancy < months or Lansky score <%
Life expectancy of >=  years
Life expectancy less than five years.
Patients with anticipated life expectancy <  months will be excluded
Life expectancy <  months (mo)
Patients being considered for RALP and pelvic lymphadenectomy with life expectancy greater than  years as determined by treating physician
Life expectancy >=  years
There are no life expectancy restrictions
Subject must have a life expectancy that exceeds the duration of the clinical trial
Individuals with a short life expectancy (<  years)
There are no restrictions on life expectancy
Life expectancy is not a consideration for protocol entry
Life expectancy of >=  months (as determined by treating physician)
A referring physicians estimate of patient life expectancy must be between - months
Patients with life expectancy of at least  months and who are expected to be able to complete the full follow-up assessment in the protocol.
Patients with distant metastatic disease (cM) or a life expectancy of less than  years
